Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
PARSIPPANY, N.J., October 11, 2023--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current anti-infective portfolio at Infectious Disease Week (IDWeek) 2023, taking place October 11-15, 2023, in Boston, MA.
IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).
Details of the presentations are provided below. The complete program of titles and abstracts can be accessed on the IDWeek 2023 website at www.idweek.org.
Melinta Portfolio Poster and Oral Presentations
Product and Presentation Type | Date/Time/ Location | Title | Poster number |
Oritavancin (poster) | Thursday, October 12 12:15 PM - 1:30 PM | Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022 | 734 |
Oritavancin (poster) | Friday, October 13 12:15 PM - 1:30 PM | Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022 | 1812 |
Rezafungin (poster) | Saturday, October 14 12:15 PM - 1:30 PM | Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program | 2115 |
Rezafungin (oral) | Friday, October 13 1:45-3:00 PM Room 102AB | Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021) | Oral presentation |
Meropenem and Vaborbactam (poster) | Saturday, October 14 12:15 PM - 1:30 PM | Activity of meropenem-vaborbactam tested against Burkholderia species isolates | 2757 |
Meropenem and Vaborbactam (poster) | Saturday, October 14 12:15 PM - 1:30 PM | Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021 | 2816 |
Meropenem and Vaborbactam (poster) | Saturday, October 14 12:15 PM - 1:30 PM | Outcomes of Timely vs. Delayed Meropenem/Vaborbactam Treatment of Infections with CRE among Adults Hospitalized in the US, 2019-2021 | 2817 |
Meropenem and Vaborbactam (poster) | Friday October 13 | PK, Safety and Tolerability of VABOMERE® (meropenem-vaborbactam) in Infants, Children and Adolescents | 1676 |
Delafloxacin (poster) | Saturday, October 14 | Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022) | 2754 |
About Melinta Therapeutics
Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO™ (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit Melinta.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011988241/en/
Contacts
Melinta Media Relations:
Sharon Dilling
Sr. Director, Corporate Communications
Melinta Therapeutics
sdilling@melinta.com
